Vertebrates are able to produce a vast repertoire of antibody molecules to combat infection. The number of antibody specificities that a human can produce during their lifetime is estimated to be in excess of 109, a number that greatly exceeds the coding capacity of the genome. Instead, the size of the antibody repertoire is the product of gene diversification processes that take place in antibody producing B lymphocytes. The primary B cell repertoire is generated by somatic (V(D)J) recombination in the bone marrow during B cell development. However, this repertoire is neither large enough nor specific enough to provide high affinity antibodies against the range of antigens an animal may encounter. Thus the generation of antibody diversity depends in a major way on secondary diversification processes that occur following V(D)J recombination. Secondary antibody diversification is triggered by deamination of cytidine residues (to yield uracil) within the immunoglobulin locus. This process is catalyzed by the cytidine deaminase AID, which is thought to bind and deaminate ssDNA exposed on the transcribed immunoglobulin gene, generating U:G mismatches that are resolved in a variety of ways to generate point mutations, gene conversion or switch recombination. However, AID-induced uracil lesions can also lead to permanent genomic damage by serving as substrates for chromosometranslocations or by mutagenizing non-Ig genes, includingoncogenes. Therefore, strict regulation of AID is importantfor maintaining genomic stability. The long term objective of this proposal is to understand how AID, and by extension antibody diversification, is regulated. This proposal will therefore focus on the following topics: a) the transcriptional regulation of AID (where we propose experiments that will determine the program that leads to induction of AID transcription); b) the regulation of AID at the protein level (where we have used a novel screen to identify the entire set of cellular factors that interact with the deaminase;and also, where we propose detailed studies on one of these cofactors, a protein termed RNF126, which appears to satisfy the requirements of a targeting factor for the deaminase). Somatic hypermutation has been implicated in autoimmune diseases as well as in the generation of B cell lymphomas. Thus the experiments proposed here are important for a better understanding of both autoimmunity and B cell lymphomas.

Public Health Relevance

The experiments proposed here are important for determining how beneficial mutation generates antibody specificities against foreign substances. The mutational process which we propose to study has been implicated in autoimmune diseases as well as in the generation of B cell lymphomas. Understanding the components involved in this process will help us gain better knowledge of the genetic and environmental causes of autoimmunity, as well as the treatment of infectious diseases and tumors.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Project (R01)
Project #
5R01CA098495-09
Application #
8208152
Study Section
Special Emphasis Panel (ZRG1-IMM-H (02))
Program Officer
Howcroft, Thomas K
Project Start
2003-04-01
Project End
2014-01-31
Budget Start
2012-02-01
Budget End
2014-01-31
Support Year
9
Fiscal Year
2012
Total Cost
$266,163
Indirect Cost
$108,670
Name
Rockefeller University
Department
Microbiology/Immun/Virology
Type
Other Domestic Higher Education
DUNS #
071037113
City
New York
State
NY
Country
United States
Zip Code
10065
Fritz, Eric L; Rosenberg, Brad R; Lay, Kenneth et al. (2013) A comprehensive analysis of the effects of the deaminase AID on the transcriptome and methylome of activated B cells. Nat Immunol 14:749-55
Rosenberg, Brad R; Hamilton, Claire E; Mwangi, Michael M et al. (2011) Transcriptome-wide sequencing reveals numerous APOBEC1 mRNA-editing targets in transcript 3' UTRs. Nat Struct Mol Biol 18:230-6
Belver, Laura; Papavasiliou, F Nina; Ramiro, Almudena R (2011) MicroRNA control of lymphocyte differentiation and function. Curr Opin Immunol 23:368-73
Davidson-Moncada, Jan; Papavasiliou, F Nina; Tam, Wayne (2010) MicroRNAs of the immune system: roles in inflammation and cancer. Ann N Y Acad Sci 1183:183-94
Fritz, Eric L; Papavasiliou, F Nina (2010) Cytidine deaminases: AIDing DNA demethylation? Genes Dev 24:2107-14
Dunnick, Wesley A; Collins, John T; Shi, Jian et al. (2009) Switch recombination and somatic hypermutation are controlled by the heavy chain 3'enhancer region. J Exp Med 206:2613-23
Delker, Rebecca K; Fugmann, Sebastian D; Papavasiliou, F Nina (2009) A coming-of-age story: activation-induced cytidine deaminase turns 10. Nat Immunol 10:1147-53
Teng, Grace; Papavasiliou, F Nina (2009) Shhh! Silencing by microRNA-155. Philos Trans R Soc Lond B Biol Sci 364:631-7
Teng, Grace; Hakimpour, Paul; Landgraf, Pablo et al. (2008) MicroRNA-155 is a negative regulator of activation-induced cytidine deaminase. Immunity 28:621-9
Teng, Grace; Papavasiliou, F Nina (2007) Immunoglobulin somatic hypermutation. Annu Rev Genet 41:107-20